U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07081932) titled 'A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood' on July 22.
Brief Summary: The main objective of this trial is to investigate the effect of bosentan, a moderate Cytochrome P450 (CYP) 3A inducer on the single dose pharmacokinetics of nerandomilast.
Study Start Date: Aug. 05
Study Type: INTERVENTIONAL
Condition:
Healthy
Intervention:
DRUG: Nerandomilast
Nerandomilast
DRUG: Bosentan
Bosentan
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Boehringer Ingelheim
Disclaimer: Curated by HT Syndication....